# Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer

> **NCT06670300** · PHASE2 · NOT_YET_RECRUITING · sponsor: **YongZhang** · enrollment: 20 (estimated)

## Conditions studied

- Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer

## Interventions

- **DRUG:** cardonilimab

## Key facts

- **NCT ID:** NCT06670300
- **Lead sponsor:** YongZhang
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06670300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06670300, "Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06670300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*